SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
THE CLINICAL, BIOLOGICAL, THERAPEUTIC AND PROGRESSIVE PROFILE OF ACUTE
LYMPHOBLASTIC LEUKEMIA IN ADULTS AND THE ELDERLY
Fatima Ezzahra Rida1, Meryem Qachouh2, Asmaa Harrach3, Nissrine Khoubila4, Siham Cherkaoui2,
Mouna Lamchahab3, Mohamed Rachid5 and Abdellah Madani5
(1)departement of clinical hematology and pediatric oncology , IBN ROCHD university hospital center,
CASABLANCA, Morocco, (2)departement of clinical hematology and pediatric oncology , IBN ROCHD
university hospital center, Casablanca, Morocco, (3)Department of clinical hematology and pediatric
oncology.Ibn Rochd University Hospital., CASABLANCA, Morocco, (4)Department of clinical hematology
and pediatric oncology.Ibn Rochd University Hospital, CASABLANCA, Morocco, (5)departement of
clinical hematology and pediatric oncology , IBN ROCHD university hospital center, casablanca, Morocco
I
ntroduction:
ALL accounts for 15% to 20% of acute leukemia in adults, although it is more common in
children. The prognosis for ALL in adults remains guarded with a probability of survival of 30%.
The objective of this work is to study the clinical, biological, therapeutic and evolutionary
characteristics of patients with ALL.
Patients and methods:
Retrospective, descriptive study, carried out at the department of clinical hematology and
pediatric oncology of the IBN ROCHD university hospital center over a period of 7 years (2012
- 2019), involving patients diagnosed with ALL aged 35 years and over. Data was collected
from medical records and data analysis was done by Excel.
Results:
100 patients were collected, the median age at diagnosis was 49 years (36-73) with a sex ratio
(M / F) of 1.12, the median consultation time was 60 days (10-180). The anemic syndrome
was the most frequent mode of disclosure: 88.4%. Tumor syndrome in 48%. Infiltrative
syndrome has been observed in 10% of cases. The initial neurological involvement was noted
in 1 patient. Major hyperleukocytosis (> 50,000 / mm3) was present in 35% of patients.
Peripheral blastosis was observed in 59% of patients. Lysis syndrome occurred in 15%.
Immunophenotyping was performed in all patients and found ALL B in 62% of patients, ALL T
in 25%, acute bi-phenotypic leukemia in 2% and inconclusive immunophenotyping in 11%.
Cytogenetic analysis was performed in 88% of patients: the karyotype was normal in 8.8% (n
= 10) of patients, t (9.22) was found in 17.6% of patients (n = 20), hypo diploidy in 8% of cases,
a complex karyotype in 4.5% and hyper diploidy in a single patient, mitosis failure was noted
in 5% of patients. FISH was performed in 12% of patients; demonstrated the BCR-ABL
transcript in 2 patients. Therapeutically 20 patients were not evaluable; 9 died before
treatment and 11 lost to follow-up. 80 patients were evaluable, 69 were treated according to
the national protocol MARALL, 6 patients according to the GRALL protocol, 2 patients
according to the GRAAPH protocol, 1 patient according to the EWALL protocol and 2 patients
had received palliative treatment. For patients treated with the MARALL protocol, 57.3% were
in remission after Induction, 13.2% died, 11% PDV and 11.7% were unsuccessful, of which 6
received salvage treatment: 1 patient was in complete remission, therapeutic failure is noted
for two patients. and 3 deaths. The patient treated by the EWALL protocol died on D12 of
treatment. After a median follow-up of 8 months, 15.15% were in remission, 39.3% died and
45.4% were lost to follow-up. Overall survival (OS) at 36 months was 23%.
POSTER 37